Novel porphyrin compounds containing benzothiazole, benzoxazole, and benzimidazole moieties have been prepared and their structures have been confirmed. Molecular docking of non-symmetric hetaryl-substituted porphyrins and chlorin e6 with SARS-CoV-2 helicase has been carried out. The affinity of hetaryl-substituted porphyrins to this protein has been found significantly higher than that of the drugs approved by the FDA and chlorin e6. The structure of the complexes of SARS-CoV-2 helicase with the considered macroheterocyclic compounds has been analyzed. Possible ways to inhibit and photoinactivate SARS-CoV helicase have been suggested basing on the localization of porphyrins and chlorin e6 in the helicase domains.
1 December 2023 in Russian Journal of General Chemistry
Directed synthesis of a new cationic monoheteryl-substituted porphyrin, 5-[4′-(1′′,3′′,7′′-trimethyixanth-2′′-yl]-10,15,20-tris-(N-methylpyridinium-3′-yl) porphyrin triiodide was carried out. This porphyrin is in a partially associated state in Tris-buffer solutions at pH = 7.4, and has a long fluorescence lifetime (~9 ns). It has been found that the synthetic nucleic acid binds the synthesized porphyrin in the groove with an affinity constant of 2.3×107. It has been shown that the porphyrin binding by poly[d(AT)2] leads to a decrease in the particle size. Photoirradiation of the porphyrin complex with poly[d(AT)2] by visible light leads to the destruction of the nucleic acid and enhances the porphyrin photolysis.
20 June 2022 in Russian Journal of General Chemistry
The results of experimental studies of the interaction of the S-protein with a monohetaryl-substituted porphyrin containing a benzimidazole residue are presented. It has been revealed that the S-protein forms high-affinity complexes with the specified porphyrin. The porphyrin binding by the SARS-CoV-2 S-protein has proceeded stepwise; at the first stage, the driving force of the complexation is electrostatic interaction between the surface negatively charged regions of the protein and cationic substituents of the porphyrin. At the second stage, the target complex of the S-protein with the porphyrin is formed. It has been established that the introduction of 5-[4′-( N -methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-( N -methyl-3′-pyridyl)porphyrin triiodide into a solution of the S-protein complex with the angiotensin-converting enzyme leads to the replacement of the latter with the porphyrin. Displacement of the angiotensin-converting enzyme from the complex with the S-protein under the action of 5-[4′-( N -methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-( N -methyl-3′-pyridyl)porphyrin triiodide is the experimental evidence for the porphyrin binding at the receptor-binding domain of the S-protein.